$BIAFJun 16, 2026, 12:06 PMAI processed
BIAF to host July webinar with Philips & 4DMedical on veteran lung screening
AI Summary
BioAffinity Technologies (NASDAQ: BIAF / BIAFW) will co-host a July 21 webinar with NAVREF, Philips and 4DMedical to showcase mobile CT, noninvasive CyPath® Lung testing and advanced functional lung imaging for U.S. veterans at higher risk of lung disease. The company highlights CyPath Lung (marketed as an LDT) and cites a published trial showing 92% sensitivity, 87% specificity and a 99% NPV for nodules <20 mm, aiming to boost VA-provider awareness and potential clinical adoption; this is an educational outreach, not a new contract or clinical readout.
Positives
- Webinar with NAVREF, Philips and 4DMedical targets VA clinicians and could raise awareness of CyPath Lung within the VA network
- Company cites published trial performance for CyPath: 92% sensitivity, 87% specificity and 99% NPV for nodules <20 mm
- Presentation includes complementary technologies (mobile CT and functional imaging) that could support integrated screening workflows
Negatives
- Announcement is an educational webinar, not a commercial agreement or government contract
- No new clinical data or regulatory milestone was announced
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) and is not intended as a sole diagnostic tool